 |
|
Antipsychotic drugs double risk of death among Alzheimer's patients
January 09, 2009New research into the effects of antipsychotic drugs commonly prescribed to Alzheimer's patients concludes that the medication nearly doubles risk of death over three years.
The study, funded by the Alzheimer's Research Trust, was led by Prof Clive Ballard's King's College London team and is published in Lancet Neurology on 9 January.
The study involved 165 Alzheimer's patients in care homes who were being prescribed antipsychotics. 83 continued treatment and the remaining 82 had it withdrawn and were instead given oral placebos.
Findings showed a significant increase in risk of death for patients who continued taking antipsychotic medication. The difference between the two groups became more pronounced over time, with 24-month survival rates for antipsychotic-treated patients falling to 46% versus 71% on the placebo and at 36 months it was 30% versus 59%. It means that after three years, less than a third of people on antipsychotics were alive compared to nearly two thirds using the dummy drug.
Antipsychotics are used to treat symptoms of agitation, delusions and aggressive behaviour. NICE guidelines recommend that the drugs should only be used for short periods of time and where symptoms are severe, and should be very carefully monitored, although in clinical practice the average length of prescription is 1-2 years. While there is evidence of modest short-term (6-12 weeks) benefits of antipsychotic treatment for the serious behavioural symptoms of Alzheimer's, a previous Alzheimer's Research Trust study showed that these benefits were not evident over longer periods of treatment.
As many as 100,000 people with dementia are routinely prescribed antipsychotics in UK care homes. It could mean 23,500 people dying prematurely, according to a 2008 report by Paul Burstow MP.
Prof Clive Ballard of King's College London said:
"The results further highlight the need to seek less harmful alternatives for the long-term treatment of behavioural symptoms in Alzheimer's patients. At the moment, there is still a limited place for antipsychotics in the treatment of Alzheimer's, particularly severe aggression, but the serious concerns of the drugs shown by our research emphasise the urgent need to put an end to unnecessary and prolonged prescribing".
Rebecca Wood, Chief Executive of the Alzheimer's Research Trust, said:
"The findings of this research are a real wake-up call and underline the danger of prescribing antipsychotics long-term for anything other than exceptional circumstances. We must avoid the use of these drugs as a potentially dangerous 'chemical cosh' to patients who would be better off without it. The study also highlights the urgent need to develop better treatments as Alzheimer's patients have few options available to them.
"700,000 people in the UK have dementia; we urgently need to fund more research to develop the new treatments we so desperately need".
Dr Mark Baxter of the University of Oxford added:
"Antipsychotic drugs can be effective in controlling unpleasant and disturbing behavioural symptoms of Alzheimer's disease, including severe aggression, delusions, and agitation. But this study shows, conclusively, that these drugs have a severe and serious cost in terms of increased mortality. The study follows the gold-standard double-blind, placebo-controlled method for clinical trials, and is unique in examining long-term effects of antipsychotic treatment on mortality in patients with Alzheimer's disease.
"Antipsychotics do not have any effects on the underlying disease processes of Alzheimer's disease. What is needed is not only an increased application of non-drug methods to improve behavioural health in patients with dementia -- including cognitive-behavioural therapy and environmental design -- as well as a better understanding of how Alzheimer's neuropathology causes behavioural disturbances in addition to its effects on memory, so that rational drug therapies can be developed that do not have the liabilities of currently-available antipsychotics."
Alzheimer's Research Trust
Findings showed a significant increase in risk of death for patients who continued taking antipsychotic medication. The difference between the two groups became more pronounced over time, with 24-month survival rates for antipsychotic-treated patients falling to 46% versus 71% on the placebo and at 36 months it was 30% versus 59%. It means that after three years, less than a third of people on antipsychotics were alive compared to nearly two thirds using the dummy drug.
Antipsychotics are used to treat symptoms of agitation, delusions and aggressive behaviour. NICE guidelines recommend that the drugs should only be used for short periods of time and where symptoms are severe, and should be very carefully monitored, although in clinical practice the average length of prescription is 1-2 years. While there is evidence of modest short-term (6-12 weeks) benefits of antipsychotic treatment for the serious behavioural symptoms of Alzheimer's, a previous Alzheimer's Research Trust study showed that these benefits were not evident over longer periods of treatment.
As many as 100,000 people with dementia are routinely prescribed antipsychotics in UK care homes. It could mean 23,500 people dying prematurely, according to a 2008 report by Paul Burstow MP.
Prof Clive Ballard of King's College London said:
"The results further highlight the need to seek less harmful alternatives for the long-term treatment of behavioural symptoms in Alzheimer's patients. At the moment, there is still a limited place for antipsychotics in the treatment of Alzheimer's, particularly severe aggression, but the serious concerns of the drugs shown by our research emphasise the urgent need to put an end to unnecessary and prolonged prescribing".
Rebecca Wood, Chief Executive of the Alzheimer's Research Trust, said:
"The findings of this research are a real wake-up call and underline the danger of prescribing antipsychotics long-term for anything other than exceptional circumstances. We must avoid the use of these drugs as a potentially dangerous 'chemical cosh' to patients who would be better off without it. The study also highlights the urgent need to develop better treatments as Alzheimer's patients have few options available to them.
"700,000 people in the UK have dementia; we urgently need to fund more research to develop the new treatments we so desperately need".
Dr Mark Baxter of the University of Oxford added:
"Antipsychotic drugs can be effective in controlling unpleasant and disturbing behavioural symptoms of Alzheimer's disease, including severe aggression, delusions, and agitation. But this study shows, conclusively, that these drugs have a severe and serious cost in terms of increased mortality. The study follows the gold-standard double-blind, placebo-controlled method for clinical trials, and is unique in examining long-term effects of antipsychotic treatment on mortality in patients with Alzheimer's disease.
"Antipsychotics do not have any effects on the underlying disease processes of Alzheimer's disease. What is needed is not only an increased application of non-drug methods to improve behavioural health in patients with dementia -- including cognitive-behavioural therapy and environmental design -- as well as a better understanding of how Alzheimer's neuropathology causes behavioural disturbances in addition to its effects on memory, so that rational drug therapies can be developed that do not have the liabilities of currently-available antipsychotics."
Alzheimer's Research Trust
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Blindness MRI Probiotic Brain function Botulinum Toxin Infectious Disease Public Health Acute Lymphoblastic Leukemia Aerosols Back Pain Delirium Colorectal Cancer Tropical Disease Breast Cancer Chronic Pain Heart Transplant Chronic Myeloid Leukemia Wildlife Conservation Plate Tectonics Stroke Damage Pathogens Diarrhea Carbon Sequestration Biofuels Antiretroviral Therapy
See More: Science News Tags
Antipsychotics Current Events and Antipsychotics News RSSNewer antipsychotics no better than older drug in treating child and adolescent schizophrenia
Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).
First generation antipsychotic drugs as effective as newer ones in some children
Nearly every child who receives an antipsychotic medicine is first prescribed one of the second-generation, or "atypical" drugs, such as olanzapine and risperidone. However, there has never been evidence that these drugs are more effective than the older, first-generation medications.
Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.
Looking beyond the drug receptor for clues to drug effectiveness
Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Violence declines with medication use in some with schizophrenia
Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Treatment With An Antipsychotic Drug Found To Cause Changes In Metabolism Earlier Than Expected
Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.
New treatment mechanisms for schizophrenia
The field of schizophrenia research has come alive with many exciting new potential approaches to treatment. From the introduction of chlorpromazine to the current day, all treatments approved by the U.S. Food and Drug Administration have had, at their core, a single treatment mechanism, the blockade of the dopamine D2 receptor.
Effectiveness of most PTSD therapies is uncertain
Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.
Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Researchers have found surprising evidence that an antidepressant (citalopram) may perform as well as a commonly-prescribed antipsychotic (risperidone) in the alleviation of severe agitation and psychotic symptoms of dementia. Researchers also found that the antidepressant was associated with "significantly lower" adverse side effects.
More Antipsychotics Current Events and Antipsychotics News Articles
 |
Stahl's Illustrated Antipsychotics by Stephen M. Stahl (Author) All of the titles in the Stahl's Illustrated Series are designed to be fun. Concepts are illustrated by full-color images that will be familiar to all readers of Stahl's Essential Psychopharmacology, Third Edition and The Prescriber's Guide. The texts in this user-friendly series can be supplements to figures, images, and tables. The visual learner will find that these books make psychopharmacology concepts easy to master, while the non-visual learner will enjoy a shortened text version of complex psychopharmacology concepts. Within each book, each chapter builds on previous chapters, synthesizing information from basic biology and diagnostics to building treatment plans and dealing with complications and comorbidities. Novices may want to approach Stahl's Illustrated Series by first... |
 |
Neurotransmitter Receptors in Actions of Antipsychotic Medications by CRC Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia, have fewer extrapyramidal side effects, are less sedating, and attempt to address the negative symptoms of schizophrenia. Neurotransmitter Receptors in Actions of Antipsychotic Medications presents a glimpse into the development of these breakthroughs and the field's current status in one definitive volume.The exhaustive chapters cover the basic knowledge of schizophrenic syndromes and provide a general description of available antipsychotic drugs.... |
 |
Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series) by Stephen M. Stahl (Author) Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr. Stephen M. Stahl has revised chapters covering antipsychotics and mood stabilizers for this third edition of Antipsychotics and Mood Stabilizers. More than one-third longer than the previous edition, Antipsychotics and Mood Stabilizers is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. This updated edition includes advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. Intended as a primer text covering all... |
 |
Atypical Antipsychotics (Milestones in Drug Therapy) by Birkhäuser Basel Univ. of Nijmegen, The Netherlands. Discusses drugs which play an important role in the therapy of schizophrenia. Written by experts in the field of schizophrenia both from a clinical and preclinical point of view. For psychiatrists, neuroscientists in the pharmaceutical industry, and medical students. DNLM: Antipsychotic Agents--therapeutic use. |
 |
Higher or Lower: Dosing Issues in the Use of Atypical Antipsychotics In spite of the great deal of clinical and basic research, the dosing strategies for atypical antipsychotics still lack a firm rational basis. The manufacturers of atypical antipsychotics recommend ranges (in mg/day) within which the products are supposed to be safe and effective. The selection of the individual patients dose within (or outside) these ranges is up to clinical judgment that should, theoretically, strike the optimal balance between the therapeutic and adverse effects. In practical terms, clinical judgment is difficult to define, and quality is hard to assess. This program will review the dosing and plasma levels of the atypical antipsychotics. |
 |
The Effects Of Anti-Psychotic Medication Forced Upon The Unfortunate Souls Who May Or May Not Need Them by Joyful Noise Recordings |
 |
America Fooled: The Truth About Antidepressants, Antipsychotics And How We've Been Deceived by Timothy Scott (Author) America Fooled is the non-sensational, fact-filled story of how Americans have come to believe that depression and other mental problems are caused by chemical imbalances which can be fixed with pills. It reveals how the drug studies used to achieve FDA approval are designed, paid for and written by the drug companies themselves and are purposely deceptive. Part 1 of America Fooled is focused on antidepressants, their effectiveness, and their side effects including the permanent brain damage that results from long-term use about which so few Americans have any knowledge (including those who prescribe and those who take antidepressants). Part 2 deals with the various approaches used throughout history to treat more serious mental problems including the use of antipsychotics. The side... |
 |
Atypical Antipsychotics: From Bench to Bedside by Taylor & Francis Showcasing the latest studies in the field, this reference unveils recent breakthroughs in the use of atypical antipsychotics for the treatment of a variety of patient populations-tracking developments in the management of patients with schizophrenia and affective psychotic disorders, as well as therapeutic regimens for children and adolescents. |
 |
Promoting Wellness: Schizophrenia (Online Tutorial for Institutions) by Adrianne Avillion and Mary Dreher, Educational Global Technologies, Inc. The goal of the online tutorial Promoting Wellness: Schizophrenia is to help healthcare professionals recognize this disorder and its impact on clients, families, and the community, and to promote treatment strategies that enhance the health and wellness of clients dealing with this disorder. This online tutorial is approved for continuing education. |
 |
Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application by Helmut Buschmann (Editor), Jörg Holenz (Editor), Antonio Párraga (Editor), Antoni Torrens (Editor), José Miguel Vela (Editor), José Luis Díaz (Editor) Antidepressants and related psychiatric drugs are the most important prescription drugs worldwide, accounting for a market volume of 20 billion US$ per year. This handbook provides a complete and detailed overview of all currently available psychiatric drugs, covering more than 250 different compounds. Particular features include: the most important information on the chemistry, pharmacology and therapeutic use of a given drug a special layout with margin notes and compound structures allowing for quick and easy access to the desired information Written by drug developers from the pharmaceutical industry, novel drugs currently under development and new methods of treatment are listed side by side with classical drugs, allowing a direct comparison... |
| © 2009 BrightSurf.com |